Childhood Cancer Genomics (PDQ®)–Health Professional Version

Changes to this Summary (11/15/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Leukemias

Editorial changes were made to the Acute Lymphoblastic Leukemia (ALL)subsection.

Added text to the Acute Myeloid Leukemia (AML) subsection about the presentation, incidence, and outcome of patients with AML and t(16;21)(q24;q22) (RUNX1-CBFA2T3 AML) (cited Noort et al. as reference 183).

Added text to the Acute Myeloid Leukemia (AML) subsection about the presentation, incidence, and outcome of patients with AML and t(16;21)(p11;q22) (FUS-ERG AML).

Langerhans Cell Histiocytosis

Added text to the Langerhans Cell Histiocytosis section to state that other BRAF mutations that result in signal activation have been described (cited Héritier et al. as reference 10).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Multiple Endocrine Neoplasia Syndromes

Next section >
About This PDQ Summary